These findings open a new avenue for a putative therapeutic strategy by blocking FGF23-FGFR4 in combination with vitamin D or its receptor to prevent or alleviate the massive cardiovascular injuries in CKD patients (Grabner et al., 2017; Leifheit-Nestler et al., 2017). The gene discussed is FGFR4; the disease is chronic kidney disease.